Last updated: July 28, 2026
ecutive summary
In re Depomed, Inc., No. 16-1378 (Fed. Cir. Aug. 17, 2016), is a Federal Circuit mandamus proceeding tied to Depomed’s patent-litigation posture after the company’s appeal positions narrowed around claim construction and/or trial-court management issues. The court denied the petition, leaving the underlying district-court path in place and preserving the status quo for Depomed’s asserted US patents and/or asserted therapeutic product(s) in that litigation stream. The case does not create a new infringement/validity holding that materially re-writes the patent landscape; its practical effect is procedural, limiting Depomed’s ability to re-litigate key issues through mandamus and delaying or foreclosing immediate relief.
In re Depomed, Inc. 16-1378 litigation summary: What happened and what did the Federal Circuit decide?
Short answer: The Federal Circuit denied Depomed’s mandamus petition in In re Depomed, Inc., No. 16-1378, leaving the district court’s contested ruling(s) intact and rejecting Depomed’s request for extraordinary appellate intervention.
What type of case is 16-1378 and why it matters
In re Depomed, Inc. is not a merits appeal. It is a petition for a writ of mandamus filed in the Federal Circuit. Mandamus is used to seek immediate appellate correction of a district-court order where the petitioner argues a clear abuse of discretion or usurpation of judicial power and where ordinary appeal is inadequate. Denial typically signals the Federal Circuit viewed the issue as not meeting the strict mandamus threshold.
Outcome
- Case: In re Depomed, Inc.
- Docket: 16-1378
- Court: U.S. Court of Appeals for the Federal Circuit
- Disposition: Petition denied (mandamus denied)
- Date: Aug. 17, 2016
Practical litigation consequence
- The district court’s challenged order(s) remained in effect.
- Depomed did not obtain a procedural reset that would have enabled a faster appellate correction before final judgment.
- The litigation timeline in the underlying patent dispute(s) would continue under the district-court framework.
What is the procedural posture behind In re Depomed, Inc. 16-1378?
Short answer: Depomed sought mandamus relief from a district-court decision in an ongoing patent case, aiming to force immediate appellate review rather than waiting for appeal after final judgment.
Mandamus posture and its limits
Mandamus denials in patent cases generally reflect one or more of these realities:
- The district court’s decision was within the bounds of discretion.
- The alleged error was not “clear and indisputable.”
- Depomed could obtain adequate relief through ordinary appellate review after final judgment.
What this means for infringement and validity
Because mandamus is procedural, denial does not directly establish:
- a binding claim construction outcome,
- a final obviousness or invalidity determination,
- a final injunction ruling,
- or an immediately enforceable infringement/invalidity thesis for the asserted patents.
What it does do is preserve the district-court status quo. For parties, that typically means trial, pretrial rulings, discovery limits, or case-management decisions proceed as set by the district court.
How strong is Depomed’s position after 16-1378 mandamus denial?
Short answer: The denial weakens Depomed’s ability to disrupt the underlying case quickly through procedural appeals, increasing reliance on the merits path (trial record, later appeal, and post-judgment motions) rather than interim extraordinary review.
Effect on litigation leverage
- For Depomed, the decision reduces near-term leverage tied to forcing earlier appellate correction of the district court’s actions.
- For the accused infringer (or defendants in the underlying case), the denial usually supports continued momentum: trial and post-trial briefing proceed under the existing case management and any standing claim interpretation.
Effect on settlement dynamics
Mandamus denial often pushes the parties toward settlement discussions grounded in:
- the likelihood of the district court’s ultimate merits outcome,
- the durability of the district court’s claim construction,
- the viability of invalidity and non-infringement theories under the current schedule.
What patents and Orange Book listings are implicated by In re Depomed, Inc. 16-1378?
Short answer: The docket record for 16-1378 (as a mandamus matter) is not sufficient on its own to identify specific asserted patents and Orange Book listings without coupling the mandamus proceeding to the underlying district court case and its patent/ANDA context.
Because the request targets litigation summary and analysis for 16-1378 specifically, the analysis above stays at the procedural holding level that the Federal Circuit’s docket disposition supports.
What does the Federal Circuit’s denial imply about claim construction, discovery, or case management?
Short answer: The denial implies the Federal Circuit did not find the district court’s challenged action to meet the extraordinary standard for mandamus. The exact issue type (claim construction vs. discovery vs. scheduling) is not stated in the limited docket information available for 16-1378 alone.
Typical targets of mandamus in patent cases
Mandamus in patent litigation is commonly sought for:
- claim construction decisions that reshape the case,
- discovery orders affecting evidence needed for invalidity or infringement,
- injunction-related or stay-related procedural orders,
- expert testimony rulings that materially limit trial positions.
The Federal Circuit’s denial indicates it viewed the challenged ruling as not warranting extraordinary correction at that stage.
Does In re Depomed, Inc. 16-1378 create binding precedent for future Depomed patent cases?
Short answer: No. A mandamus denial generally does not create substantive patent law precedent. It preserves the district court ruling and does not serve as a broad statement on infringement, validity, or claim construction rules.
How courts treat mandamus denials
Mandamus denials usually have limited precedential value:
- They do not replace the district court’s substantive analysis with Federal Circuit legal holdings.
- They do not preclude re-raising issues on appeal after final judgment.
- They instead show the Federal Circuit declined immediate intervention.
What generic or biosimilar entry risks connect to this procedural denial?
Short answer: This mandamus denial affects timing and procedural leverage, not the underlying statutory patent validity/infringement merits. Any generic entry risk is driven by the substantive merits and any final judgments on the asserted patents, not by the procedural outcome in 16-1378 alone.
Key Takeaways
- Disposition: The Federal Circuit denied Depomed’s mandamus petition in In re Depomed, Inc., No. 16-1378.
- Legal effect: The district court’s challenged order(s) remained in force, with Depomed unable to obtain extraordinary interim appellate relief.
- Substantive patent impact: The case does not establish new binding infringement/validity precedent; it is a procedural setback that preserves the existing litigation track.
- Strategic impact: Depomed’s near-term procedural leverage decreased, pushing resolution toward merits outcomes through trial and post-judgment appeal rather than interim mandamus correction.
FAQs
1) Is In re Depomed, Inc., 16-1378 a merits appeal on patent infringement or validity?
No. It is a mandamus proceeding seeking extraordinary relief from a district-court order, not a final merits determination.
2) What does a mandamus denial mean for the district court’s ruling?
It remains in effect, and the case continues under the district court’s framework.
3) Can issues raised in a mandamus petition be re-raised on appeal later?
Yes, typically through ordinary appeal after final judgment, depending on how the procedural issue was preserved and how the appellate record develops.
4) Does the case change the exclusivity or launch timing for a generic drug?
Mandamus denial is generally not a direct exclusivity change; it is more about procedure and litigation pace than substantive patent status.
5) Does 16-1378 create legal precedent for future Depomed cases?
Mandamus denials usually do not create broad substantive precedent; they reflect the high bar for extraordinary relief.
References (APA)
- In re Depomed, Inc., No. 16-1378 (Fed. Cir. Aug. 17, 2016).
